<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d135" origId="Bevacizumab"><sentence id="DrugDDI.d135.s0" origId="s0" text="No formal drug interaction studies with anti-neoplastic agents have been conducted."><entity charOffset="40-62" id="DrugDDI.d135.s0.e0" origId="s0.p2" text="anti-neoplastic agents" type="drug"/><negationtags>&lt;xcope&gt;&lt;cue&gt;No&lt;/cue&gt; formal drug interaction studies with anti-neoplastic agents have been conducted&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d135.s1" origId="s1" text="In Study 1, patients with colorectal cancer were given irinotecan/5-FU/leucovorin (bolus-IFL) with or without AVASTIN."><entity charOffset="55-65" id="DrugDDI.d135.s1.e0" origId="s1.p11" text="irinotecan" type="drug"/><entity charOffset="110-117" id="DrugDDI.d135.s1.e1" origId="s1.p17" text="AVASTIN" type="drug"/><pair e1="DrugDDI.d135.s1.e0" e2="DrugDDI.d135.s1.e1" id="DrugDDI.d135.s1.p0" interaction="false"/><negationtags>In Study 1, patients with colorectal cancer were given irinotecan/5-FU/leucovorin (bolus-IFL) with or &lt;xcope&gt;&lt;cue&gt;without&lt;/cue&gt; AVASTIN&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d135.s2" origId="s2" text="Irinotecan concentrations were similar in patients receiving bolus-IFL alone and in combination with AVASTIN."><entity charOffset="0-10" id="DrugDDI.d135.s2.e0" origId="s2.p18" text="Irinotecan" type="drug"/><entity charOffset="101-108" id="DrugDDI.d135.s2.e1" origId="s2.p26" text="AVASTIN" type="drug"/><pair e1="DrugDDI.d135.s2.e0" e2="DrugDDI.d135.s2.e1" id="DrugDDI.d135.s2.p0" interaction="false"/></sentence><sentence id="DrugDDI.d135.s3" origId="s3" text="The concentrations of SN38, the active metabolite of irinotecan, were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone."><entity charOffset="32-49" id="DrugDDI.d135.s3.e0" origId="s3.p29" text="active metabolite" type="drug"/><entity charOffset="53-63" id="DrugDDI.d135.s3.e1" origId="s3.p30" text="irinotecan" type="drug"/><entity charOffset="144-151" id="DrugDDI.d135.s3.e2" origId="s3.p37" text="AVASTIN" type="drug"/><pair e1="DrugDDI.d135.s3.e0" e2="DrugDDI.d135.s3.e1" id="DrugDDI.d135.s3.p0" interaction="false"/><pair e1="DrugDDI.d135.s3.e0" e2="DrugDDI.d135.s3.e2" id="DrugDDI.d135.s3.p1" interaction="false"/><pair e1="DrugDDI.d135.s3.e1" e2="DrugDDI.d135.s3.e2" id="DrugDDI.d135.s3.p2" interaction="true"/></sentence><sentence id="DrugDDI.d135.s4" origId="s4" text="In Study 1, patients receiving bolus-IFL plus AVASTIN had a higher incidence of Grade 3-4 diarrhea and neutropenia."><entity charOffset="46-53" id="DrugDDI.d135.s4.e0" origId="s4.p46" text="AVASTIN" type="drug"/></sentence><sentence id="DrugDDI.d135.s5" origId="s5" text="Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain."><entity charOffset="135-145" id="DrugDDI.d135.s5.e0" origId="s5.p60" text="irinotecan" type="drug"/><entity charOffset="150-157" id="DrugDDI.d135.s5.e1" origId="s5.p62" text="AVASTIN" type="drug"/><pair e1="DrugDDI.d135.s5.e0" e2="DrugDDI.d135.s5.e1" id="DrugDDI.d135.s5.p0" interaction="true"/></sentence></document>